Christina Rossi Sells 2,274 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) Stock

Blueprint Medicines Co. (NASDAQ:BPMC) COO Christina Rossi sold 2,274 shares of Blueprint Medicines stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $101.75, for a total transaction of $231,379.50. Following the completion of the transaction, the chief operating officer now directly owns 66,992 shares of the company’s stock, valued at $6,816,436. This trade represents a 3.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Christina Rossi also recently made the following trade(s):

• On Monday, March 24th, Christina Rossi sold 2,274 shares of Blueprint Medicines stock. The stock was sold at an average price of $95.02, for a total transaction of $216,075.48.

Blueprint Medicines Trading Down 0.8 %

Shares of BPMC stock opened at $98.96 on Friday. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. The stock has a 50-day simple moving average of $88.32 and a 200 day simple moving average of $93.67. Blueprint Medicines Co. has a fifty-two week low of $73.04 and a fifty-two week high of $121.90. The stock has a market capitalization of $6.39 billion, a P/E ratio of -91.63 and a beta of 0.83.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.32). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. The business had revenue of $149.41 million during the quarter, compared to analyst estimates of $158.31 million. During the same period in the prior year, the firm earned $1.40 EPS. The business’s revenue for the quarter was up 55.5% on a year-over-year basis. On average, sell-side analysts expect that Blueprint Medicines Co. will post -1.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on BPMC shares. Wolfe Research began coverage on Blueprint Medicines in a research report on Tuesday, March 18th. They set an “outperform” rating on the stock. StockNews.com raised shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a report on Friday, May 2nd. Wedbush restated an “outperform” rating and set a $128.00 price target on shares of Blueprint Medicines in a research report on Thursday, May 1st. Jefferies Financial Group assumed coverage on shares of Blueprint Medicines in a research report on Monday, March 17th. They issued a “buy” rating and a $135.00 price objective on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $135.00 target price on shares of Blueprint Medicines in a research report on Friday, May 2nd. Five analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Blueprint Medicines has a consensus rating of “Moderate Buy” and a consensus target price of $126.56.

Institutional Investors Weigh In On Blueprint Medicines

A number of institutional investors and hedge funds have recently modified their holdings of BPMC. Avoro Capital Advisors LLC acquired a new stake in shares of Blueprint Medicines during the fourth quarter worth $103,356,000. Norges Bank purchased a new position in Blueprint Medicines in the 4th quarter worth about $62,028,000. Jennison Associates LLC acquired a new stake in Blueprint Medicines during the 4th quarter worth about $31,417,000. Rock Springs Capital Management LP boosted its holdings in shares of Blueprint Medicines by 42.7% in the fourth quarter. Rock Springs Capital Management LP now owns 1,096,899 shares of the biotechnology company’s stock worth $95,672,000 after buying an additional 328,123 shares during the period. Finally, Wellington Management Group LLP boosted its holdings in shares of Blueprint Medicines by 8.0% in the fourth quarter. Wellington Management Group LLP now owns 4,281,364 shares of the biotechnology company’s stock worth $373,421,000 after buying an additional 316,754 shares during the period.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.